Irinotecan pharmacogenomics

S Marsh, JM Hoskins - Pharmacogenomics, 2010 - Taylor & Francis
Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-
threatening toxicities can occur from irinotecan treatment. Although multiple genes may play …

eHealth: past and future perspectives

T Rooij, S Marsh - Personalized Medicine, 2016 - Taylor & Francis
eHealth is an umbrella term incorporating any area that combines healthcare and
technology to improve efficiencies and reduce costs. The ultimate goal of eHealth is to …

Personalized medicine policy challenges: measuring clinical utility at point of care

T Van Rooij, DM Wilson, S Marsh - Expert review of …, 2012 - Taylor & Francis
Pharmacogenomics, driven by advances in genomics, helps to explain patients' individual
variability in response to therapies. Personalized medicine, the application of the increasing …

Personalized Medicine: A Solution for Today and Tomorrow

B Dalbayrak, MD Metiner - European Journal of Biology, 2022 - dergipark.org.tr
Personalized medicine is a multidisciplinary area that contains several techniques to
provide patients with more efficient, cheaper, and fewer side effects treatment strategies. In …

[图书][B] Applying pharmacogenomics in therapeutics

X Feng, HG Xie - 2016 - books.google.com
Recent advances in high-throughput gene sequencing and other omics biotechnologies
have served as a springboard for the field of pharmacogenomics. Pharmacogenomics is …

Fast and frugal trees: translating population-based pharmacogenomics to medication prioritization

T Rooij, M Roederer, T Wareham, I Rooij… - Personalized …, 2015 - Taylor & Francis
Aim: Fast and frugal decision trees (FFTs) can simplify clinical decision making by providing
a heuristic approach to contextual guidance. We wanted to use FFTs for pharmacogenomic …

Improving oncology outcomes through targeted therapeutics will require electronic delivery systems

T Rooij, S Marsh - Future Oncology, 2011 - Taylor & Francis
Typically, chemotherapy selection takes into account patient demographic data, including
disease symptoms, family history, environmental factors and concurrent medications …

eHealth and mHealth Pipelines for Clinical Decision Support to Improve Medication Selection and Safety

TW Van Rooij - 2015 - era.library.ualberta.ca
Although much work has been done over the past decade on developing personalized and
evidence-based medicine, such as diagnostic tests based on genetics to better predict …

[引用][C] Regulatory Considerations in Pharmacogenomics at EMA and US FDA.

M Paulmichl, M Maliepaard, M Papaluca… - … : An Introduction and …, 2012 - pure.pmu.ac.at
Regulatory Considerations in Pharmacogenomics at EMA and US FDA. — PMU
Forschungsportal Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt …